Collectively, we found that the 6q14.3 deletion decreased SH3BGRL2 expression, which downregulated the O‐linked glycan biosynthesis, ultimately weakening the EMT process, inhibiting the tumor cell growth, and resulting in a good prognosis for patients with CCA (Figure 2P). The gene discussed is SH3BGRL2; the disease is cholangiocarcinoma.